

Niklas Gebauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7452011/publications.pdf>

Version: 2024-02-01

22
papers

325
citations

932766

10
h-index

887659

17
g-index

24
all docs

24
docs citations

24
times ranked

504
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of nutritional and inflammation-based risk scores in follicular lymphoma in the era of anti-CD20 targeted treatment strategies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1789-1801.	1.2	5
2	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. <i>Blood Advances</i> , 2022, 6, 637-651.	2.5	15
3	Mutational landscape of high-grade B-cell lymphoma with <i>MYC</i> , <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing. <i>Haematologica</i> , 2022, 107, 1850-1863.	1.7	17
4	Mutational and immunologic Landscape in malignant Salivary Gland Tumors harbor the potential for novel therapeutic strategies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103592.	2.0	4
5	Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	5
6	Exhaustion of tumour-infiltrating T-cell receptor repertoire diversity is an age-dependent indicator of immunological fitness independently predictive of clinical outcome in Burkitt lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 138-149.	1.2	9
7	Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements. <i>Cancers</i> , 2021, 13, 887.	1.7	7
8	Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3043-3050.	1.2	6
9	Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing. <i>Blood Cancer Journal</i> , 2021, 11, 102.	2.8	28
10	Autoimmune neutropenia associated with heterozygous variant of <i>SBS1</i> gene mimicking Shwachman-Bodian-Diamond syndrome. <i>Leukemia and Lymphoma</i> , 2021, 62, 3047-3050.	0.6	1
11	Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma. <i>Blood Advances</i> , 2021, 5, 5220-5225.	2.5	13
12	Comparative analysis of international prognostic indices in gray-zone lymphoma. <i>Leukemia and Lymphoma</i> , 2021, , 1-9.	0.6	1
13	Clinicopathological characteristics and <i>MYC</i> status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients. <i>Blood Cancer Journal</i> , 2020, 10, 63.	2.8	10
14	Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr Virus positive diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2020, 189, 257-268.	1.2	21
15	The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation. <i>Cancers</i> , 2020, 12, 921.	1.7	15
16	Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate. <i>Cancers</i> , 2020, 12, 873.	1.7	34
17	The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 869-873.	1.2	6
18	Trofosamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 129-136.	1.2	8

#	ARTICLE	IF	CITATIONS
19	Favorable prognostic impact of <i>RAS</i> mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective. <i>Leukemia and Lymphoma</i> , 2016, 57, 226-229.	0.6	8
20	Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly. <i>Leukemia and Lymphoma</i> , 2015, 56, 1100-1106.	0.6	43
21	<i>TP53</i> mutations are frequent events in double-hit B-cell lymphomas with <i>MYC</i> and <i>BCL2</i> but not <i>MYC</i> and <i>BCL6</i> translocations. <i>Leukemia and Lymphoma</i> , 2015, 56, 179-185.	0.6	57
22	MicroRNA-150 is up-regulated in extranodal marginal zone lymphoma of MALT type. <i>Cancer Genomics and Proteomics</i> , 2014, 11, 51-6.	1.0	10